Samsung Biologics KRX:207940KOSPI
삼성바이오로직스 · Korean news coverage and regulatory filings, organized.
Articles, 24h11
Articles, 7 days76
DART filings, 7 days5
Articles tracked76since Sep 11
In Q2 2026, Samsung Biologics reported revenue of ₩1.32tn, up 2.4% year on year, and operating profit of ₩586bn. Samsung Biologics (삼성바이오로직스) appeared in 76 Korean news articles and 5 DART filings over the past seven days. Coverage peaked on Sep 11 with 35 articles. The most common catalyst was contracts & orders (4). It was most often mentioned alongside Hanmi Pharm and Celltrion.
Samsung Biologics quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩1.32tn | +2.4% | ₩586bn | ₩431bn |
| Q1 2026 | ₩1.26tn | -3.2% | ₩581bn | ₩469bn |
| Q4 2025 derived | ₩309bn | -75.4% | ₩378bn | ₩510bn |
| Q3 2025 | ₩1.66tn | +39.9% | ₩729bn | ₩574bn |
| Q2 2025 | ₩1.29tn | +11.5% | ₩476bn | ₩324bn |
| Q1 2025 | ₩1.30tn | +37.1% | ₩487bn | ₩376bn |
| Q4 2024 derived | ₩1.26tn | +17.0% | ₩326bn | ₩321bn |
| Q3 2024 | ₩1.19tn | +14.8% | ₩339bn | ₩264bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
Samsung Biologics top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6
Latest Samsung Biologics news Korean headlines
-
삼성바이오 노사 2차 사후조정 연기…갈등해소 '요원'
1 more on this story · 1 outlets
- 삼성바이오 노사 2차 사후조정 연기…갈등해소 '요원'연합뉴스경제 · 08:59
-
삼성바이오에피스, 임직원 가족 2800여명 초청 행사
1 more on this story · 1 outlets
- 삼성바이오에피스, 임직원 가족 2800명 송도 사옥 초청…5년째 행사 이어가PRESS9 · Sep 14 10:01
-
제약株 브랜드평판 1위 삼성바이오로직스…셀트리온·한미약품 추격
2 more on this story · 2 outlets
- [빅데이터로본다] 제약 상장기업 2026년 9월 브랜드평판... 1위 삼성바이오로직스, 2위 셀트리온, 3위 한미약품일간투데이 · Sep 14 06:58
- 제약 상장기업 2026년 9월 브랜드평판...삼성바이오로직스, 셀트리온, 한미약품 順에너지신문 · Sep 14 08:59
-
삼성바이오에피스, 5년째 임직원 가족들과 '소통'
1 more on this story · 1 outlets
- 삼성바이오에피스, 5년째 임직원 가족들과 '소통'메드월드뉴스 · Sep 13 22:37
